Study #2016-0677
EFFORT: EFFicacy Of ceralasertib (AZD6738) and adavosertib (AZD1775) in parp ResisTance; A Randomized 3-arm non-comparative Phase 2 Study of adavosertib alone, adavosertib plus olaparib, and ceralasertib plus olaparib in Women with Ovarian Cancer who have
MD Anderson Study Status
Not Accepting
Treatment Agent
Adavosertib, Olaparib, Ceralasertib
Description
This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Adavosertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Study phase:
Phase II
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.